The firm has multiple catalysts that could generate a rally of 35 for the stock.
BioNTech SE (BNTX) — Live Session & Technical Brief
Updated Nov 21, 2026 5:03 AM ET · Prev Close $81.38
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-0.52%) in Biotechnology
BioNTech SE (Bntx) is trading within a tight intraday band at $80.96 (-0.52%, 1.68x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BNTX is outperforming the S&P 500 by +3.12%. 14-day RSI stands at 32.1, keeping momentum in a bearish regime.
The firm has multiple catalysts that could generate a rally of 35 for the stock.
Price ($80.96) trades relative to 20-day SMA ($86.32) and 50-day SMA ($91.52).
Market & Sector Relative Strength
BNTX outperforming the S&P 500 by +3.12%Recent BNTX Catalyst Headlines
Verified WireBioNTech has seen its share price fall sharply over the past few years, even as the business shifts away from a single Covid-19 product toward a broader oncology portfolio. With the stock now trading well below its earli
Arbutus Biopharma and Genevant have expanded their patent infringement actions against Pfizer and BioNTech by adding new lawsuits in Japan and updating a Canadian case to include a recently issued lipid nanoparticle pate
BioNTech NasdaqGS BNTX is back in focus after Arbutus Biopharma and Genevant expanded their patent enforcement campaign by filing new lawsuits in Japan and updating an existing Canadian case tied to mRNA lipid nanopartic
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $86.32 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (BNTX)
BEARISH MA TRENDRetail & Crowd Sentiment
NeutralAbout BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered …
Get Instant BNTX Catalyst Alerts
Receive an email alert when BNTX triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversBNTX Session & Catalyst FAQ
Why is BNTX stock trading near flat today?
BioNTech SE (Bntx) is trading within a tight intraday band at $80.96 (-0.52%, 1.68x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, BNTX is outperforming the S&P 500 by +3.12%. 14-day RSI stands at 32.1, keeping momentum in a bearish regime.
Is BNTX stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 1.68x relative volume (high participation). Our multi-factor model currently rates BNTX as HOLD. Review full valuation, quality, and timing signals on the BNTX Buy or Sell Decision Brief →
What is BNTX's intrinsic value and expected trading range?
At $80.96, BNTX's modeled 1-to-3 session range is $78.93 – $82.99, with a key inflection level at $86.32 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the BNTX Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for BNTX?
RSI at 32.1 reflects soft below-midline momentum. BNTX trades at $80.96 relative to its 20-day SMA ($86.32) and 50-day SMA ($91.52), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.